Biopharmaceutical company developing therapies for retinal diseases.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapies for retinal diseases. At the forefront of its portfolio is KSI-301, an innovative anti-vascular endothelial growth factor antibody biopolymer currently undergoing Phase IIb/III clinical trials. This promising candidate aims to address conditions such as wet age-related macular degeneration (AMD), diabetic macular edema, macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
In addition to KSI-301, Kodiak Sciences Inc. is actively developing other promising products in its pipeline. This includes KSI-501, a bispecific conjugate designed to target retinal diseases accompanied by inflammatory components, and KSI-601, a triplet inhibitor specifically tailored for the treatment of dry AMD. These preclinical stage candidates underscore the company's commitment to addressing unmet medical needs in ophthalmology.
Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences Inc. originally operated under the name Oligasis, LLC before rebranding in 2015. The company's location in the heart of Silicon Valley positions it at the nexus of innovation and biomedical research, facilitating collaborations and advancements in therapeutic development.
Kodiak Sciences Inc. continues to leverage its deep expertise in biopolymer technology and ophthalmic research to pioneer novel treatments that offer hope to patients suffering from debilitating retinal diseases. With a strong emphasis on scientific rigor and patient outcomes, the company remains dedicated to transforming the landscape of ophthalmology through its innovative approach and pipeline advancements.